To determine whether neuronal deletion of cannabinoid receptor 2 (CB2R) in NeuroD6-positive neurons reduces the frequency and severity of levodopa-induced dyskinesia (LID) in a Parkinson’s disease (PD) mouse model.
PD is defined by progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). While levodopa remains the cornerstone of PD treatment, chronic use often causes LID, characterized by involuntary, hyperkinetic movements driven by pulsatile dopamine levels that alter cortico-basal ganglia activity. CB2R is implicated in neuroinflammation, yet its contribution to LID remains unclear. Preliminary work suggests that neuronal, rather than microglial, CB2R deletion influences dysregulation underlying LID.
Neuronal CB2R deletion mitigated AIMs, suggesting it may play a role in modulating LID in PD mouse model; however, larger sample sizes are needed to validate findings.